Also known as: Xarelto
Bayer outlined its 2030 growth strategy at Pharma Media Day 2026, driven by AI partnerships, precision medicine, and a strengthened pipeline. The company aims for mid-single-digit growth from 2027 and 30% margins by 2030.
The global biopharmaceutical industry entered 2026 facing one of the largest waves of patent expirations in its history, with $200-300 billion in yearly sales at risk through 2032 as major drugs lose exclusivity.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07699796 |
Apixaban vs Rivaroxaban vs No Anticoagulant to Prevent EHIT After Great Saphenous Vein Laser Ablation |
COMPLETED | PHASE4 |
| NCT07618988 |
Rivaroxaban in Pediatric Patients With DVT |
COMPLETED | PHASE4 |
| NCT07599384 |
Emulation of the RECORD3 Trial Using Healthcare Claims Data |
COMPLETED | |
| NCT07318610 |
Reducing Adverse Vascular Outcomes With Factor XI Inhibition in Adult Participants With Peripheral Artery Disease |
RECRUITING | PHASE3 |
| NCT07312851 |
A Study to Investigate Andexanet Dosing and the Interaction Between Andexanet and Subsequent Enoxaparin in Healthy Participants |
COMPLETED | PHASE1 |
| NCT06953726 |
Comparing the Safety and Efficacy of Apixaban and Rivaroxaban |
RECRUITING | PHASE4 |
| NCT06370273 |
Thromboprophylaxis in Lower Limb Immobilisation |
RECRUITING | PHASE3 |
| NCT05735639 |
THRomboprophylaxis in Individuals Undergoing Superficial endoVEnous Treatment (THRIVE) |
RECRUITING | PHASE4 |
| NCT05410275 |
Chronic Anticoagulation With a Reduced Dose Regimen of Rivaroxaban in End-stage Renal Disease Patients |
RECRUITING | PHASE3 |
| NCT05180773 |
Impact of Bromocriptine on Clinical Outcomes for Peripartum Cardiomyopathy |
RECRUITING | PHASE4 |
